COCRYSTAL PHARMA NEW O.N. (8CC) — Financial Flexibility Index
COCRYSTAL PHARMA NEW O.N. (8CC) has a Financial Flexibility Index of -0.51x as of December 2025. Free cash flow of €-1.74 Million (operating CF €-1.74 Million minus capex €0.00) represents -1% of total liabilities (€3.38 Million).
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
COCRYSTAL PHARMA NEW O.N. Financial Flexibility Index (2021–2025)
Historical Financial Flexibility Index trend for COCRYSTAL PHARMA NEW O.N. across 5 annual periods. See COCRYSTAL PHARMA NEW O.N. working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for COCRYSTAL PHARMA NEW O.N. (2021–2025)
Year-by-year free cash flow to debt coverage for COCRYSTAL PHARMA NEW O.N.. For the full company profile including market capitalisation, see COCRYSTAL PHARMA NEW O.N. (8CC) total market value.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -2.42x | €-8.18 Million | €-8.19 Million | €3.38 Million | ▲ +42.2% |
| 2024 | -4.19x | €-16.48 Million | €-16.48 Million | €3.93 Million | ▼ -40.4% |
| 2023 | -2.98x | €-14.55 Million | €-14.67 Million | €4.88 Million | ▲ +82.2% |
| 2022 | -16.78x | €-21.36 Million | €-21.43 Million | €1.27 Million | ▼ -144.1% |
| 2021 | -6.87x | €-12.67 Million | €-12.72 Million | €1.84 Million | — |